Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:06 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 11,404 matching trials from the live ClinicalTrials.gov search.
Filters: Seattle, Washington Clear all
Completed Phase 1Phase 2 Interventional

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects

NCT00162045
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
4 Years to 16 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Miami, Florida • Honolulu, Hawaii • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Nov 3, 2026, 1:06 PM EST
Completed Not applicable Interventional

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

NCT00118339
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
chemoprotection, complementary or alternative medicine procedure, management of therapy complications
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 3 Interventional Results available

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

NCT01178281
View directory record Official record
Conditions
Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions
Pomalidomide 0.5 mg, Placebo, Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Nov 3, 2026, 1:06 PM EST
Terminated Phase 1 Interventional

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

NCT05336409
View directory record Official record
Conditions
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 3, 2026, 1:06 PM EST
Active, not recruiting Phase 3 Interventional

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
36
States / cities
Daphne, Alabama • Chandler, Arizona • Prescott Valley, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 1:06 PM EST
Not yet recruiting No phase listed Observational

Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.

NCT07909005
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Interventions
Local laboratory testing, Local Lab Tests
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Up to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 2 Interventional Results available

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

NCT01767194
View directory record Official record
Conditions
Ganglioneuroblastoma, Recurrent Neuroblastoma
Interventions
Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Sargramostim, Temozolomide, Temsirolimus
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 106 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Nov 3, 2026, 1:06 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users

NCT06909500
View directory record Official record
Conditions
Nicotine Dependence, Tobacco-Related Carcinoma
Interventions
Smartphone app, Text Message, Survey Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 3 Interventional

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

NCT00084071
View directory record Official record
Conditions
Pneumonia
Interventions
Tifacogin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
51
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001037
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 4 Interventional Results available

RNS® System LTT Study

NCT00572195
View directory record Official record
Conditions
Epilepsy
Interventions
RNS® System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 3, 2026, 1:06 PM EST
Completed No phase listed Observational

ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

NCT01534819
View directory record Official record
Conditions
Aortic Aneurysm
Interventions
EndoAnchor™, endovascular treament
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

NCT02918019
View directory record Official record
Conditions
Asthma
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 3, 2026, 1:06 PM EST
Not listed Not applicable Interventional

Unobtrusive Sensing of Medication Intake ("USE-MI")

NCT03571022
View directory record Official record
Conditions
Medication Adherence
Interventions
USE-MI System
Behavioral
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Nov 3, 2026, 1:06 PM EST
Active, not recruiting Phase 1 Interventional

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

NCT04192981
View directory record Official record
Conditions
Brain Metastases, Leptomeningeal Metastasis
Interventions
GDC-0084, whole brain radiation therapy radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

NCT01059630
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
33
States / cities
Mobile, Alabama • Casa Grande, Arizona • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 3, 2026, 1:06 PM EST
Recruiting Phase 1 Interventional

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807
View directory record Official record
Conditions
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions
Emicizumab
Drug
Lead sponsor
Bleeding and Clotting Disorders Institute Peoria, Illinois
Other
Eligibility
0 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
12
States / cities
Orange, California • Redwood City, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 3 Interventional Results available

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

NCT00050011
View directory record Official record
Conditions
Breast Neoplasms, Osteoporosis
Interventions
Zoledronic Acid, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
43
States / cities
Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Nov 3, 2026, 1:06 PM EST
Terminated Phase 2 Interventional Results available

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT03256045
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Chemosensitivity Assay, Dexamethasone, Laboratory Biomarker Analysis, Panobinostat
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Nov 3, 2026, 1:06 PM EST
Not listed No phase listed Observational

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

NCT04131036
View directory record Official record
Conditions
Hemophilia A
Interventions
assessment of joint health and bone density
Other
Lead sponsor
Washington Institute for Coagulation
Other
Eligibility
16 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Nov 3, 2026, 1:06 PM EST
Completed Not applicable Interventional

Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study

NCT02137044
View directory record Official record
Conditions
Multiple Sclerosis, Pain, Depression
Interventions
Collaborative Care (CC)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Nov 3, 2026, 1:06 PM EST
Terminated Phase 2 Interventional Results available

AMG 827 in Subjects With Psoriatic Arthritis

NCT01516957
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AMG 827 140, Placebo, AMG 827 280, AMG 827 210
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Nov 3, 2026, 1:06 PM EST
Completed Phase 3 Interventional

Exercise to Improve Sleep in Heart Failure

NCT00194701
View directory record Official record
Conditions
Heart Failure
Interventions
Walking exercise
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Nov 3, 2026, 1:06 PM EST